If potent IFN-based agents, whether administered for prevention or early treatment of a viral infection, can be developed, and stored in sufficient quantities, the negative impact of future unrecognized viral respiratory epidemics may be mitigated early in the response while pathogen-specific agents are being developed. The gene discussed is IFNA1; the disease is viral infectious disease.